Rosnilimab
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Rosnilimab
- anb 030
- ANB-030
- anb030
- ANB030
- immunoglobulin g1 anti human programmed cell death protein 1 human mus musculus monoclonal anb030 gamma 1 chain disulfide with human mus musculus monoclonal anb030 kappa chain dimer
- IMMUNOGLOBULIN G1, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN-MUS MUSCULUS MONOCLONAL ANB030 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL ANB030 .KAPPA.-CHAIN, DIMER
- rosnilimab
- Rosnilimab
- rosnilimab [INN]
- ROSNILIMAB [USAN]
- Rosnilimab [WHO-DD]
- rosnilimab inn
- rosnilimab usan
- rosnilimab who dd
- CAS registry numbers
- 2412764-40-8
- ChEMBL ID
- CHEMBL5095287
- FDA ingredient codes (UNII)
- 93OKX5KD2L
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- rosnilimab
- Type
- Antibody
- Drug name stem
- -mab
- Action
- Agonist
- Action type
- Agonist
- Target
- programmed cell death 1 (CD279)
- Gene symbol
- PDCD1
- Protein identifier
- Q15116
- Median affinity
- 6.3
- Affinity units
- pIC50
- Action
- Agonist
- Action type
- Agonist
- Target
- programmed cell death 1 (CD279)
- Gene symbol
- PDCD1
- Protein identifier
- Q15116
- Median affinity
- 10.29
- Affinity units
- pKd
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Colitis, Ulcerative
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000729
- Subject identifier
- D003093
- Condition
- Alopecia Areata
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004192
- Subject identifier
- D000506
- Condition
- Autoimmune Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005809
- Subject identifier
- D001327
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000729
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004192
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005809
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005340
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007179
- Condition identifier
- MONDO_0008383
- Highest recorded phase
- 2
- NCT05205070
- NCT06041269
- NCT06127043
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLVQSGSELKKPGASVKVSCKASNYTFTDYSMHWVRQAPGQGLEWMGWINIETYYPTYADQFKGRFAFSLDTSVSTAYLQISSLKAEDTAVYYCARDYYGRFYYAMDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
- Component
- Light chain
- Type
- Protein
- Sequence
- EIVLTQSPATLSLSPGERATLSCTASSSVSSSYFHWYQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKKVYACEVTHQVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 301 $ 301''''
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-89' $ 23'''-89''' $ 135'-195' $ 135'''-195''' $ 148-204 $ 148''-204'' $ 224-215' $ 224''-215''' $ 230-230'' $ 233-233'' $ 265-325 $ 265''-325'' $ 371-429 $ 371''-429''
- Component
- Glycosylation sites (N)
- Sequence
- 301 $ 301''
Related records
Trials (3)
- A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
- A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
- A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
In development for (4)
- Alopecia areata Phase 2
- Autoimmune disease Phase 2
- Rheumatoid arthritis Phase 2
- Ulcerative colitis Phase 2